Cardiometabolic risk in polycystic ovary syndrome

被引：42
|
作者：
Studen, Katica Bajuk [1 ]
Pfeifer, Marija [2 ]
机构：
[1] Univ Med Ctr Ljubljana, Nucl Med Dept, Ljubljana, Slovenia
[2] Univ Ljubljana, Fac Med, Ljubljana, Slovenia
来源：
ENDOCRINE CONNECTIONS | 2018年 / 7卷 / 07期
关键词：
PCOS; cardiovascular risk; cardiometabolic risk; hyperandrogenism; obesity; OBSTRUCTIVE SLEEP-APNEA; IMPAIRED GLUCOSE-TOLERANCE; INTIMA-MEDIA THICKNESS; CORONARY-ARTERY-DISEASE; FATTY LIVER-DISEASE; HORMONE-BINDING GLOBULIN; INSULIN-RESISTANCE; CARDIOVASCULAR-DISEASE; METABOLIC SYNDROME; OBESE WOMEN;
D O I：
10.1530/EC-18-0129
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Polycystic ovary syndrome (PCOS) is a common disorder in women of reproductive age. Besides hyperandrogenism, oligomenorrhea and fertility issues, it is associated with a high prevalence of metabolic disorders and cardiovascular risk factors. Several genetic polymorphisms have been identified for possible associations with cardiometabolic derangements in PCOS. Different PCOS phenotypes differ significantly in their cardiometabolic risk, which worsens with severity of androgen excess. Due to methodological difficulties, longer time-scale data about cardiovascular morbidity and mortality in PCOS and about possible beneficial effects of different treatment interventions is missing leaving many issues regarding cardiovascular risk unresolved.
引用
收藏
页码：R238 / +
页数：14
相关论文
共 50 条
  • [21] Impact of Lisinopril on Cardiometabolic Risk Factors in Sisters of Women With Polycystic Ovary Syndrome
    Krysiak, Robert
    Kowalcze, Karolina
    Okopien, Boguslaw
    JOURNAL OF CLINICAL PHARMACOLOGY, 2023, 63 (09): : 1045 - 1052
  • [22] The Impact of Atorvastatin on Cardiometabolic Risk Factors in Sisters of Women with Polycystic Ovary Syndrome
    Krysiak, Robert
    Kowalcze, Karolina
    Okopien, Boguslaw
    PHARMACOLOGY, 2023, 108 (05) : 451 - 459
  • [23] The impact of atorvastatin on cardiometabolic risk factors in brothers of women with polycystic ovary syndrome
    Robert Krysiak
    Witold Szkróbka
    Bogusław Okopień
    Pharmacological Reports, 2021, 73 : 261 - 268
  • [24] Serum visfatin as predictive marker of cardiometabolic risk in women with polycystic ovary syndrome
    Rashad, Nearmeen M.
    Abd-Elrahman, M. N. Ayman
    El-Shal, Amal S.
    Amin, Abdelaziz I.
    MIDDLE EAST FERTILITY SOCIETY JOURNAL, 2018, 23 (04) : 335 - 341
  • [25] Does body weight affect cardiometabolic risk in women with polycystic ovary syndrome?
    Dokras, Anuja
    FERTILITY AND STERILITY, 2019, 111 (01) : 56 - 57
  • [26] Antimullerian hormone levels and cardiometabolic risk in young women with polycystic ovary syndrome
    Feldman, Rebecca A.
    O'Neill, Kathleen
    Butts, Samantha F.
    Dokras, Anuja
    FERTILITY AND STERILITY, 2017, 107 (01) : 276 - 281
  • [27] Oral contraceptive plus antiandrogen therapy and cardiometabolic risk in polycystic ovary syndrome
    Harmanci, Ayla
    Cinar, Nese
    Bayraktar, Miyase
    Yildiz, Bulent Okan
    CLINICAL ENDOCRINOLOGY, 2013, 78 (01) : 120 - 125
  • [28] Association of severity of menstrual dysfunction with cardiometabolic risk markers in polycystic ovary syndrome
    Li, X.
    Chen, X.
    Yang, J.
    Lin, M.
    Li, C.
    Deng, L.
    Wu, H.
    Hu, Y.
    HUMAN REPRODUCTION, 2023, 38
  • [29] Cystatin C, a novel cardiometabolic risk marker in women with polycystic ovary syndrome
    Yildirim, Aysegul
    Yildizhan, Begum
    Ilhan, Gokce Anik
    Pekin, Tanju
    GYNECOLOGICAL ENDOCRINOLOGY, 2016, 32 (06) : 457 - 459
  • [30] The impact of atorvastatin on cardiometabolic risk factors in brothers of women with polycystic ovary syndrome
    Krysiak, Robert
    Szkrobka, Witold
    Okopien, Boguslaw
    PHARMACOLOGICAL REPORTS, 2021, 73 (01) : 261 - 268
12345